missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Shigella dysenteriae 1 Monoclonal Antibody (M81)

Beschreibung
This antibody is specific for S. dysenteriae serotype 1 and does not cross-react with S. boydii, S. flexneri and other S. dysenteriae serotypes.
Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide. Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually. Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid. The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness. Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases. Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus. Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.
Spezifikation
Spezifikation
| Antigen | Shigella dysenteriae 1 |
| Anwendungen | Immunocytochemistry |
| Klassifikation | Monoclonal |
| Klon | M81 |
| Konzentration | 1.0 mg/mL |
| Konjugat | Unconjugated |
| Zusammensetzung | PBS with 10 mM sodium azide |
| Gen-Alias | S. dysenteriae; shigella; shigellosis |
| Wirtsspezies | Mouse |
| Immunogen | Native Shigella dysenteriae. |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?